PTH and hypoparathyroidism: Later, the more stable recombinant human PTH1−84 has been approved for the treatment of hypoparathyroidism.(11) Nevertheless, as hypoparathyroidism is a rare disease with few controlled trials, and PTH has multiple systemic targets, the management and safety of PTH replacement therapy—and the ideal candidates for such a therapy—have yet to be established.(12)